Vitamin D Repletion for Adults with Serum 25‑Hydroxyvitamin D ≈ 25 ng/mL

Severity Assessment & Therapeutic Target

A serum 25‑hydroxyvitamin D level of 25 ng/mL falls into the insufficient range (20–29 ng/mL) and warrants active correction to reach ≥30 ng/mL for optimal musculoskeletal, cardiovascular, and immune health (American College of Endocrinology & American Association of Clinical Endocrinology) 1.
The recommended therapeutic window is 30–50 ng/mL; levels above 50 ng/mL do not provide additional clinical benefit compared with the 30–44 ng/mL range (American College of Endocrinology & American Association of Clinical Endocrinology) 2.

Standard loading regimen: 50,000 IU vitamin D₃ once weekly for 8 weeks (total 400,000 IU). This regimen is expected to raise serum 25‑hydroxyvitamin D by ≈ 40–60 ng/mL, moving most patients into the target range (American College of Endocrinology & American Association of Clinical Endocrinology) 1.
Formulation preference: Vitamin D₃ is strongly preferred over vitamin D₂ because it sustains serum concentrations longer and produces greater increases in 25‑hydroxyvitamin D (American College of Endocrinology & American Association of Clinical Endocrinology) 2.
Safety of weekly high‑dose regimen: In adults without granulomatous disease or primary hyperparathyroidism, the weekly 50,000 IU regimen does not cause hypercalcemia or toxicity (Praxis Medical Insights) 3.

Daily high‑dose option: 5,000 IU vitamin D₃ daily for 8–12 weeks provides repletion efficacy comparable to the weekly bolus while avoiding large intermittent serum spikes (American College of Endocrinology & American Association of Clinical Endocrinology) 2.
Physiologic advantage: Daily dosing maintains more stable serum 25‑hydroxyvitamin D levels and improves adherence compared with intermittent bolus regimens (Praxis Medical Insights) 4.
Special indications: The daily high‑dose approach is especially appropriate for patients with malabsorption syndromes, obesity (BMI > 30), or those taking enzyme‑inducing medications (e.g., anticonvulsants, glucocorticoids, rifampin) (Praxis Medical Insights) 3.

Follow‑up testing: Re‑measure serum 25‑hydroxyvitamin D 8–12 weeks after therapy initiation to confirm an adequate response (American College of Endocrinology & American Association of Clinical Endocrinology) 2.
Insufficient response: If the level remains <30 ng/mL despite confirmed adherence, increase the maintenance dose to 3,000–6,000 IU daily and evaluate for underlying malabsorption (Praxis Medical Insights) 3.
Referral threshold: Persistent inadequate response after dose escalation warrants referral to an endocrinology specialist for complex management (The Endocrine Society) 5.

Standard maintenance: After achieving ≥30 ng/mL, continue with 2,000 IU vitamin D₃ daily for long‑term maintenance; this dose is considered absolutely safe and does not require routine laboratory monitoring (Autoimmunity Reviews) 1.
Dose‑response rule of thumb: Each additional 1,000 IU/day typically raises serum 25‑hydroxyvitamin D by ≈ 10 ng/mL, though individual responses vary with body weight, baseline level, and absorption capacity (Autoimmunity Reviews) 1.
Higher‑dose maintenance for special groups: Obese individuals or those with malabsorption may require 3,000–6,000 IU daily to sustain target levels (Praxis Medical Insights) 3.

Avoid large annual bolus: Regimens such as 500,000 IU once yearly are associated with increased falls, fractures, and adverse outcomes in older adults (American College of Endocrinology & American Association of Clinical Endocrinology) 2.
Low‑dose insufficiency: Daily doses of 800–1,000 IU are generally insufficient to correct deficiency in most adults and should not be used as initial therapy (The Endocrine Society) 5.
Upper safety limit: Serum 25‑hydroxyvitamin D concentrations >100 ng/mL are considered the upper safety threshold; toxicity (hypercalcemia) is rare and occurs only with chronic daily doses >50,000 IU that raise levels >150 ng/mL (Autoimmunity Reviews) 1.
Monitoring in high‑risk conditions: Patients with active granulomatous disease (e.g., sarcoidosis, tuberculosis, lymphoma) or primary hyperparathyroidism should have serum calcium monitored closely during supplementation (American College of Endocrinology & American Association of Clinical Endocrinology) 2.

Obesity (BMI > 30): Require 2–3 × standard dose (6,000–10,000 IU daily or 50,000 IU twice weekly for 8 weeks) because adipose tissue sequesters vitamin D, reducing circulating levels (Praxis Medical Insights) 3.
Malabsorption syndromes (celiac disease, Crohn’s disease, cystic fibrosis, chronic pancreatitis): May need 6,000–10,000 IU daily to achieve target serum concentrations (The Endocrine Society) 5.
Enzyme‑inducing medications (phenytoin, carbamazepine, rifampin, glucocorticoids): Recommend higher maintenance doses of 4,000–6,000 IU daily to offset increased vitamin D metabolism (Praxis Medical Insights) 3.

Frequency preference: Daily or weekly dosing is recommended over large single‑time bolus administrations, as frequent dosing better mimics physiologic cutaneous production and avoids excessive 24‑hydroxylation that inactivates vitamin D (American College of Endocrinology & American Association of Clinical Endocrinology) 2.
Vitamin D₃ vs. D₂: Vitamin D₃ is preferred because it avoids assay‑specificity problems and maintains serum levels longer with intermittent dosing (Autoimmunity Reviews & American College of Endocrinology) 1.
Daily equivalence: When dosing daily, vitamin D₂ and D₃ achieve comparable serum concentrations, but vitamin D₃ remains the guideline‑recommended standard (Autoimmunity Reviews) 1.

Adequate calcium intake: Ensure 1,000–1,200 mg of calcium per day (dietary plus supplemental) to optimize bone health and enhance the clinical response to vitamin D therapy (Praxis Medical Insights) 3.
Supplementation necessity: Calcium supplementation is not required solely for treating vitamin D deficiency unless dietary calcium intake is insufficient (Praxis Medical Insights) 4.